These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24975891)

  • 61. Gastrointestinal symptoms: a comparison between patients undergoing peritoneal dialysis and hemodialysis.
    Dong R; Guo ZY; Ding JR; Zhou YY; Wu H
    World J Gastroenterol; 2014 Aug; 20(32):11370-5. PubMed ID: 25170224
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Hyperphosphatemia in dialysis: which binder?].
    Alfieri C; Malberti F; Mazzaferro S; Gallieni M; Russo D; Messa P; Cozzolino M
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234231
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder.
    Calò LA; Savica V; Piccoli A; Fusaro M; D'Angelo A; Davis PA
    Ren Fail; 2011; 33(1):11-4. PubMed ID: 21219199
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children.
    Abdullah S; Diezi M; Sung L; Dupuis LL; Geary D; Abla O
    Pediatr Blood Cancer; 2008 Jul; 51(1):59-61. PubMed ID: 18240167
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
    Chertow GM; Burke SK; Lazarus JM; Stenzel KH; Wombolt D; Goldberg D; Bonventre JV; Slatopolsky E
    Am J Kidney Dis; 1997 Jan; 29(1):66-71. PubMed ID: 9002531
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Effect of Rhubarb Combined Medicinal Activated Carbon on Levels of Serum Phosphorus, Calci- um-Phosphorus Product, and Parathyroid Hormone in Hemodialysis Patients with Hyperphosphatemia].
    Xu Q; Gong JH; Yuan H; Qin YF; Liu JJ; Lu L; Gao D
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Jul; 36(7):797-800. PubMed ID: 30634204
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    J Ren Nutr; 2014 Jul; 24(4):261-7. PubMed ID: 24836401
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phosphate binder choice in dialysis patients: a call for evidence-based rather than marketing-based clinical practice.
    Winkelmayer WC; Tonelli M
    Am J Kidney Dis; 2008 Mar; 51(3):362-5. PubMed ID: 18295050
    [No Abstract]   [Full Text] [Related]  

  • 69. The Relationship Between Intradialytic Nutrition and Gastrointestinal Symptoms Using a Modified Version of the Gastrointestinal Symptom Rating Scale.
    Kistler BM; Biruete A; Chapman-Novakofski K; Wilund KR
    J Ren Nutr; 2018 Mar; 28(2):129-134. PubMed ID: 29471989
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Control of hyperphosphatemia beyond phosphate.
    Evenepoel P
    Kidney Int; 2007 Mar; 71(5):376-9. PubMed ID: 17315005
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pre-treatment of dairy and breast milk with sevelamer hydrochloride and sevelamer carbonate to reduce phosphate.
    Raaijmakers R; Houkes LM; Schröder CH; Willems JL; Monnens LA
    Perit Dial Int; 2013; 33(5):565-72. PubMed ID: 23636435
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study.
    Koiwa F; Yokoyama K; Fukagawa M; Akizawa T
    J Ren Nutr; 2017 Sep; 27(5):346-354. PubMed ID: 28550969
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial.
    Akizawa T; Tsuruta Y; Okada Y; Miyauchi Y; Suda A; Kasahara H; Sasaki N; Maeda Y; Suzuki T; Matsui N; Niwayama J; Suzuki T; Hara H; Asano Y; Komemushi S; Fukagawa M
    BMC Nephrol; 2014 Jun; 15():98. PubMed ID: 24968790
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis.
    Ramos R; Chazot C; Ferreira A; Di Benedetto A; Gurevich K; Feuersenger A; Wolf M; Arens HJ; Walpen S; Stuard S
    BMC Nephrol; 2020 Dec; 21(1):530. PubMed ID: 33287733
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Images of the Month: Gastric Pneumatosis Due to Sevelamer-Mediated Necrosis.
    Amer S; Nguyen C; DePetris G
    Am J Gastroenterol; 2015 Jun; 110(6):799. PubMed ID: 26052763
    [No Abstract]   [Full Text] [Related]  

  • 76. A systematic review on the efficacy and safety of PA21 versus sevelamer in dialysis patients.
    Xie D; Ye N; Li M
    Int Urol Nephrol; 2018 May; 50(5):905-909. PubMed ID: 29294216
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study.
    Lee CT; Wu IW; Chiang SS; Peng YS; Shu KH; Wu MJ; Wu MS
    J Nephrol; 2015 Feb; 28(1):105-13. PubMed ID: 24840781
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Low Continuity Rate of Sucroferric Oxyhydroxide among Japanese Hemodialysis Patients with High Phosphate Binder Pill Burden].
    Mitsuboshi S; Yamada H; Nagai K; Okajima H
    Yakugaku Zasshi; 2018; 138(1):135-139. PubMed ID: 29311459
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy and safety of SBR759, a new iron-based phosphate binder.
    Block GA; Brillhart SL; Persky MS; Amer A; Slade AJ
    Kidney Int; 2010 May; 77(10):897-903. PubMed ID: 20375984
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial.
    Yin J; Yin J; Lian R; Li P; Zheng J
    BMC Nephrol; 2021 Jul; 22(1):243. PubMed ID: 34210293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.